Skip to main content

Credelio Plus

New Content Item


This collection was created to facilitate access to manuscripts published in Parasites & Vectors focusing on Credelio® Plus.

Credelio® Plus is an antiparasitic veterinary medicinal product containing a minimum dose of 20 mg/kg lotilaner and 0.75 mg/kg milbemycin oxime as active substances, which belong to the isoxazoline and macrocyclic lactones class of parasiticides, respectively. Credelio® Plus is administered monthly as an oral chewable tablet to dogs with, or at risk from, mixed infestations/infections of ticks, fleas, gastrointestinal nematodes, heartworm and/or lungworm.

The manuscripts in this collection contain data supporting the efficacy and safety of Credelio® Plus. All manuscripts have undergone the journals standard peer review process overseen by the Editors and each article can be found individually in the journal. 

The studies presented in this collection and all journal charges for processing these manuscripts have been funded by Elanco Animal Health and a detailed conflict of interest is included within each article.

EDITORIAL
Credelio® Plus: a novel oral endectocide for dogs
Donato Traversa

Parasites & Vectors 2021 14:286
Published on: 28 May 2021

>Full Text          >PDF


RESEARCH
Long-term and acute safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) in juvenile and adult dogs
Kari L. Riggs & Scott Wiseman 

Parasites & Vectors 2021 14:285
Published on: 28 May 2021

>Full text          >PDF


RESEARCH
Effectiveness of Credelio® Plus, a novel chewable tablet containing milbemycin oxime and lotilaner for the treatment of larval and immature adult stages of Toxocara canis in experimentally infected dogs
Lisa M. Young, Scott Wiseman, Elizabeth Crawley, Dwight D. Bowman, Craig R. Reinemeyer & Daniel E. Snyder 

Parasites & Vectors 2021 14:256
Published on: 28 May 2021

>Full text          >PDF


RESEARCH
Effectiveness of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) for the treatment of larval and immature adult stages of Ancylostoma caninum in experimentally infected dogs
Daniel E. Snyder, Scott Wiseman, Elizabeth Crawley, Kim Wallace, Dwight D. Bowman & Craig R. Reinemeyer 

Parasites & Vectors 2021 14:255
Published on: 28 May 2021

>Full text          >PDF


RESEARCH
Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural intestinal nematode infections in dogs presented as veterinary patients in Europe
Brad Hayes, Scott Wiseman & Daniel E. Snyder 

Parasites & Vectors 2021 14:258
Published on: 28 May 2021

>Full text          >PDF


RESEARCH
Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) for the prevention of heartworm disease (Dirofilaria immitis) in client-owned dogs in the USA
Lisa M. Young, Scott Wiseman, Elizabeth Crawley, Kim Wallace & Daniel E. Snyder 

Parasites & Vectors 2021 14:284
Published on: 28 May 2021

>Full text          >PDF


RESEARCH
Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural flea and tick infestations on dogs presented as veterinary patients in Europe
Sophie Forster, Scott Wiseman & Daniel E. Snyder 

Parasites & Vectors 2021 14:299
Published on: 4 June 2021

>Full text          >PDF